Front Row Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.59K | Hold |
2
| – | – | ﹤0.01% | 516 |
|
|
2026
Q1 | $1.54K | Hold |
2
| – | – | ﹤0.01% | 510 |
|
|
2025
Q4 | $1.54K | Hold |
2
| – | – | ﹤0.01% | 500 |
|
|
2025
Q3 | $1.13K | Sell |
2
-1
| -33% | -$565 | ﹤0.01% | 507 |
|
|
2025
Q2 | $1.57K | Sell |
3
-1
| -25% | -$558 | ﹤0.01% | 482 |
|
|
2025
Q1 | $2.54K | Hold |
4
| – | – | ﹤0.01% | 442 |
|
|
2024
Q4 | $2.85K | Hold |
4
| – | – | ﹤0.01% | 430 |
|
|
2024
Q3 | $4.21K | Hold |
4
| – | – | ﹤0.01% | 417 |
|
|
2024
Q2 | $4.2K | Hold |
4
| – | – | ﹤0.01% | 759 |
|
|
2024
Q1 | $3.85K | Hold |
4
| – | – | ﹤0.01% | 768 |
|
|
2023
Q4 | $3.51K | Hold |
4
| – | – | ﹤0.01% | 393 |
|
|
2023
Q3 | $3.29K | Hold |
4
| – | – | ﹤0.01% | 750 |
|
|
2023
Q2 | $3K | Hold |
4
| – | – | ﹤0.01% | 770 |
|
|
2023
Q1 | $3K | Buy |
+4
| New | +$3.02K | ﹤0.01% | 780 |
|
|
2022
Q4 | – | Sell |
-4
| Closed | -$3K | – | 930 |
|
|
2022
Q3 | $3K | Hold |
4
| – | – | ﹤0.01% | 765 |
|
|
2022
Q2 | $2K | Hold |
4
| – | – | ﹤0.01% | 840 |
|
|
2022
Q1 | $3K | Hold |
4
| – | – | ﹤0.01% | 816 |
|
|
2021
Q4 | $3K | Hold |
4
| – | – | ﹤0.01% | 841 |
|
|
2021
Q3 | $2K | Hold |
4
| – | – | ﹤0.01% | 875 |
|
|
2021
Q2 | $3K | Hold |
4
| – | – | ﹤0.01% | 833 |
|
|
2021
Q1 | $2K | Sell |
4
-31
| -89% | -$15.1K | ﹤0.01% | 876 |
|
|
2020
Q4 | $17K | Hold |
35
| – | – | 0.01% | 412 |
|
|
2020
Q3 | $18K | Hold |
35
| – | – | 0.01% | 393 |
|
|
2020
Q2 | $22K | Sell |
35
-1
| -3% | -$568 | 0.01% | 330 |
|
|
2020
Q1 | $19K | Sell |
36
-2
| -5% | -$825 | 0.01% | 342 |
|
|
2019
Q4 | $14K | Hold |
38
| – | – | 0.01% | 394 |
|
|
2019
Q3 | $11K | Buy |
38
+4
| +12% | +$1.18K | 0.01% | 426 |
|
|
2019
Q2 | $11K | Sell |
34
-3
| -8% | -$999 | 0.01% | 422 |
|
|
2019
Q1 | $15K | Buy |
37
+4
| +12% | +$1.65K | 0.01% | 381 |
|
|
2018
Q4 | $12K | Hold |
33
| – | – | 0.01% | 373 |
|
|
2018
Q3 | $12K | Hold |
33
| – | – | 0.01% | 398 |
|
|
2018
Q2 | $12K | Buy |
33
+6
| +22% | +$1.88K | 0.01% | 422 |
|
|
2018
Q1 | $9K | Buy |
+27
| New | +$9.39K | 0.01% | 458 |
|
Other funds holding REGN
Front Row Advisors's REGN Position: Q2 2026 in Review
Front Row Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 2 shares worth $1.59K. The position accounts for ﹤0.01% of the portfolio, ranked #516.
Front Row Advisors first reported a position in REGN in Q1 2018 and has held it in 33 quarters since. The position peaked at $22K in Q2 2020. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Front Row Advisors held 2 shares of Regeneron Pharmaceuticals worth $1.59K as of Q2 2026.
- Front Row Advisors left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
- Regeneron Pharmaceuticals made up ﹤0.01% of Front Row Advisors's portfolio in Q2 2026, its #516 holding.
- Front Row Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 33 quarters since.
- Front Row Advisors's Regeneron Pharmaceuticals position peaked at $22K in Q2 2020.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.